§ Claim under review · Mixed
"ER-100, an experimental gene therapy delivering three Yamanaka factors (OCT4, SOX2, KLF4) to optic nerve-associated cells for partial epigenetic reprogramming, has been administered to its first human patient in a Phase 1 trial testing safety in optic nerve diseases like open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy" SECONDARY CLAIM (on-image text): "the world's first cellular age-reversal treatment has officially entered human trials"
Verdict
Mostly accurate
Confidence
HighSummary
This one checks out. Life Biosciences did announce on June 9, 2026 that the first person had been dosed in a Phase 1 trial of ER-100, a gene therapy that delivers three Yamanaka factors, OCT4, SOX2 and KLF4, to retinal cells. The trial is registered publicly as NCT07290244 and enrolls people with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. It is a safety trial, the therapy goes into one eye only, and the gene activity is switched on by taking doxycycline for eight weeks. The post's headline graphic calling it the "world's first cellular age-reversal treatment" oversells things, because nothing has actually been reversed in any human yet, but the post's own caption correctly says this is not proof that aging can be reversed and is not a whole-body treatment. Worth knowing: the only source for the dosing event is the company itself, several outside scientists have publicly called the approach high-risk and doubt it will work, and the Nature Biotechnology link cited in the caption could not be verified. No results of any kind exist yet.
Why this verdict
Evidence
Every element of the primary claim is corroborated. Life Biosciences announced on June 9, 2026 that the first participant had been dosed in its Phase 1 clinical trial of ER-100, a therapy intended to treat optic neuropathies including open-angle glaucoma and NAION, with the trial evaluating safety and tolerability plus additional endpoints assessing visual function.
ER-100 is the first clinical candidate from the company's Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4, to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression.
The trial exists in the public registry. FDA IND clearance was announced January 28, 2026, allowing a Phase 1 first-in-human study (NCT07290244) enrolling individuals with open-angle glaucoma and NAION to assess safety, tolerability, immune responses and impact on multiple visual assessments.
Independent outlets treat the "first" framing as defensible but contested. ScienceAlert reported that other scientists call the approach "extraordinarily high-risk" and are skeptical it will work at all, while quoting Sinclair that the study is the first opportunity to test whether restoring epigenetic information can ameliorate human disease.
Findings
✓ What's accurate 9
- ER-100 exists, is real, and is sponsored by Life Biosciences
- It delivers three Yamanaka factors, OCT4, SOX2 and KLF4, deliberately excluding c-Myc
- First human dosing was announced June 9, 2026
- It is a Phase 1 trial primarily testing safety and tolerability
- The indications are open-angle glaucoma and NAION
- The trial is registered on ClinicalTrials.gov as NCT07290244
- The "partial epigenetic reprogramming" description matches the company's own platform language
- The caption's own disclaimers are correct: this is not proof of human aging reversal and is not a whole-body treatment
- The "first in humans" framing is supported by FDA-clearance reporting and multiple independent outlets
≈ What's misleading 4
- Imprecision, minor: the claim says the therapy is delivered "to optic nerve-associated cells." The actual target is retinal ganglion cells in the retina, reached by intravitreal injection. Their axons form the optic nerve, so the phrasing is loose rather than wrong. It does not change the meaning materially.
- Exaggeration, in the image overlay only: "the world's first cellular age-reversal treatment" describes an intended mechanism as an achieved property. Nothing has been reversed in any human. A more accurate phrasing is "first therapy designed to partially reverse cellular epigenetic age." The caption text corrects this, but the headline graphic is what most viewers will retain.
- Omitted qualifier: the post does not mention that the doxycycline-activated switch, the 8-week activation window, the sequential OAG-then-NAION cohort structure, or the significant expert skepticism about safety and durability are part of the picture.
- Omitted qualifier: the primary source is a company press release about its own product. No independent party has confirmed the dosing event or any outcome.
? What's uncertain 4
- The Nature Biotechnology citation in the caption (nature.com/articles/s41587-026-03037-z) could not be located. Searches for that DOI returned other Nature Biotechnology articles but not this one. It may exist behind indexing gaps, or the identifier may be incorrect. Treat that specific citation as unverified.
- Number of participants dosed, dose level administered, and site of administration were not disclosed in the material found.
- Whether the first participant was in the OAG escalation cohort is implied by the trial design but not explicitly confirmed in the announcement text found.
- No safety or efficacy data exist yet. None should be expected for some time.
Sources
3 of 8 linked to recordsLife Biosciences press release, "First Patient Dosed in Phase 1 Trial of ER-100," June 9, 2026
ClinicalTrials.gov registration NCT07290244
Life Biosciences press release, FDA IND clearance, January 28, 2026
ScienceAlert, "World First: Patient Receives High-Risk Therapy to Make Cells Young Again," June 10, 2026
Washington Times, June 16, 2026
Paul Knoepfler (UC Davis stem cell biologist), The Niche, February 2026
Ophthalmology Times, non-human primate data reporting, 2026
Longevity.Technology, January 29, 2026; Fight Aging!, February 2026